Get the current market trends in your inbox
Stay on top of the current market patterns and financial insights with the Axios Markets newsletter. Register for complimentary.
Capture up on coronavirus stories and special reports, curated by Mike Allen everyday
Capture up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Capture up on the most essential stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Capture up on the most crucial stories affecting your home town with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most crucial stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Capture up on the most crucial stories affecting your home town with Axios Tampa-St. Petersburg
Illustration: Annelise Capossela/Axios
The Food and Drug Administration on Tuesday authorized the first over the counter, at-home quick coronavirus test, which allows users to get their results from an app.
The big image: A multitude of at-home tests remain in advancement, which might make diagnostics simpler and faster as the pandemic rages on.
The state of play: A number of business are dealing with at-home test packages that deliver outcomes digitally, the Wall Street Journal notes
- Ellume, the company that got FDA authorization for its at-home test on Tuesday, is working on a function that would let users share their results with their physician and local health authorities.
- The FDA asked Lucira Health, which is working on a rapid test, to establish a mobile app or website for much better information tracking.
- Gauss Surgical and Cellex’s test would need users take an image of their outcomes for an algorithm’s analysis.
- On Wednesday, the BinaxNOW COVID-19 Ag Card House Test was authorized for use by patients at home with a prescription, and will be coupled with telehealth choices.
Comments
Post a Comment